Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Stock Has Average Target Price of $11.00 According to Analysts

Posted by on Sep 29th, 2026

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX – Get Free Report) has earned an average rating of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $11.00.

Separately, Weiss Ratings upgraded Evaxion A/S from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 9th.

Check Out Our Latest Report on Evaxion A/S

Evaxion A/S Price Performance

Shares of NASDAQ EVAX opened at $3.24 on Tuesday. The business has a fifty day moving average price of $3.10 and a two-hundred day moving average price of $3.54. Evaxion A/S has a fifty-two week low of $2.77 and a fifty-two week high of $12.15. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.06 and a quick ratio of 5.06. The stock has a market capitalization of $29.22 million, a PE ratio of -2.68 and a beta of 0.26.

Institutional Trading of Evaxion A/S

A number of hedge funds have recently made changes to their positions in EVAX. Rathbones Group PLC bought a new stake in Evaxion A/S in the first quarter valued at approximately $170,000. Renaissance Technologies LLC acquired a new stake in Evaxion A/S in the first quarter worth $146,000. Finally, Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of Evaxion A/S in the 1st quarter valued at about $112,000. 11.04% of the stock is owned by institutional investors and hedge funds.

Evaxion A/S Company Profile

(Get Free Report)

Evaxion A/S is a Denmark-based biotechnology company that develops immunotherapies and vaccines using artificial intelligence. Its proprietary AI-Immunology platform is designed to analyze biological data, identify disease targets and support the development of treatments tailored to individual patients or specific pathogens.

The company’s research has focused primarily on personalized cancer vaccines and vaccines for infectious diseases. Its pipeline has included EVX-01, an individualized cancer immunotherapy candidate intended to stimulate a patient’s immune system to recognize and attack tumor-specific targets, as well as additional programs directed at cancer and infectious diseases.

Evaxion was founded in Denmark and conducts its research and development activities from the country, serving the international biotechnology and pharmaceutical markets.

Featured Stories

Analyst Recommendations for Evaxion A/S (NASDAQ:EVAX)

Receive News & Ratings for Evaxion A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion A/S and related companies with MarketBeat.com's FREE daily email newsletter.